Twist Bioscience (NASDAQ:TWST) Shares Gap Down – What’s Next?

Twist Bioscience Corporation (NASDAQ:TWST)’s stock price gapped down prior to trading on Thursday. The stock had previously closed at $122.59, but opened at $99.72. Twist Bioscience shares last traded at $106.9530, with a volume of 1,497,585 shares trading hands.

More Twist Bioscience News

Investors following TWST have been watching these news items:

• Positive Sentiment: Fiscal Q4 revenue rose 26.7% year over year to $126.64 million, topping estimates, while the $0.32-per-share loss was narrower than consensus forecasts. Article
• Positive Sentiment: Management forecast Q1 fiscal 2027 revenue of $130 million–$132 million, above the $126.3 million consensus estimate. Full-year revenue guidance of $550 million–$560 million also modestly exceeded the $549 million consensus. Article
• Negative Sentiment: Despite those headline beats, coverage described the FY2027 outlook as underwhelming, suggesting it did not meet investor expectations. Continued losses and cost pressure may also have weighed on sentiment, helping explain the stock’s decline. Article

Analysts Set New Price Targets

Several analysts have recently weighed in on TWST shares. Piper Sandler increased their price target on shares of Twist Bioscience from $85.00 to $115.00 and gave the company an “overweight” rating in a research note on Wednesday, August 5th. UBS Group began coverage on Twist Bioscience in a research report on Wednesday, September 9th. They issued a “neutral” rating and a $144.00 price objective for the company. Canaccord Genuity Group increased their price objective on Twist Bioscience from $120.00 to $205.00 and gave the stock a “buy” rating in a research report on Monday, October 12th. TD Cowen raised their target price on Twist Bioscience from $115.00 to $190.00 and gave the stock a “buy” rating in a research note on Tuesday, October 13th. Finally, Jefferies Financial Group initiated coverage on Twist Bioscience in a research report on Thursday, October 8th. They issued a “hold” rating and a $150.00 target price on the stock. Seven investment analysts have rated the stock with a Buy rating, three have assigned a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $153.00.

Twist Bioscience Price Performance

The company has a quick ratio of 2.38, a current ratio of 2.67 and a debt-to-equity ratio of 0.03. The company has a market cap of $7.00 billion, a price-to-earnings ratio of -50.64 and a beta of 2.25. The stock’s 50-day simple moving average is $150.90 and its 200 day simple moving average is $92.37.

Twist Bioscience (NASDAQ:TWST) last posted its earnings results on Thursday, November 12th. The company reported ($0.32) earnings per share for the quarter, beating the consensus estimate of ($0.39) by $0.07. The firm had revenue of $126.64 million during the quarter, compared to the consensus estimate of $123.55 million. Twist Bioscience had a negative net margin of 31.66% and a negative return on equity of 28.64%. The company’s revenue for the quarter was up 26.7% compared to the same quarter last year. On average, equities research analysts anticipate that Twist Bioscience Corporation will post -2.11 EPS for the current fiscal year.

Insider Buying and Selling at Twist Bioscience

In related news, SVP Paula Green sold 1,007 shares of the firm’s stock in a transaction that occurred on Tuesday, November 3rd. The stock was sold at an average price of $135.40, for a total transaction of $136,347.80. Following the transaction, the senior vice president owned 105,625 shares in the company, valued at $14,301,625. This trade represents a 0.94% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CAO Robert F. Werner sold 1,482 shares of Twist Bioscience stock in a transaction on Friday, October 2nd. The shares were sold at an average price of $188.88, for a total transaction of $279,920.16. Following the completion of the transaction, the chief accounting officer directly owned 42,917 shares in the company, valued at $8,106,162.96. The trade was a 3.34% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last quarter, insiders sold 495,279 shares of company stock worth $80,489,387. 3.08% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Twist Bioscience

Several large investors have recently modified their holdings of the stock. E Fund Management Hong Kong Co. Ltd. acquired a new stake in shares of Twist Bioscience in the 3rd quarter worth $280,000. Westpac Banking Corp boosted its holdings in shares of Twist Bioscience by 156.7% in the third quarter. Westpac Banking Corp now owns 15,660 shares of the company’s stock valued at $3,026,000 after acquiring an additional 9,560 shares in the last quarter. Private Advisor Group LLC acquired a new position in shares of Twist Bioscience during the third quarter worth about $523,000. Ieq Capital LLC increased its stake in shares of Twist Bioscience by 7.5% during the third quarter. Ieq Capital LLC now owns 54,948 shares of the company’s stock worth $10,618,000 after acquiring an additional 3,839 shares during the period. Finally, Stephens Investment Management Group LLC increased its stake in shares of Twist Bioscience by 1.7% during the third quarter. Stephens Investment Management Group LLC now owns 780,419 shares of the company’s stock worth $150,808,000 after acquiring an additional 13,055 shares during the period.

About Twist Bioscience

Twist Bioscience Corporation is a biotechnology company that uses a silicon-based platform to manufacture synthetic DNA. Its technology supports the production of many DNA sequences in parallel for research and commercial applications. The company provides synthetic genes, gene fragments and oligonucleotide pools, as well as tools for next-generation sequencing, including target-enrichment products. Through its biopharma business, Twist also offers antibody discovery and related services to support the development of therapeutics.